Regulatory FDA hands BeOne, Taiho approvals for blood cancers PharmaphorumBeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.HematologyRead full story pharminent May 14, 2026 (Last updated: May 21, 2026) Pharmaphorum BeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho’s Inqovi has acute myeloid leukaemia added to its label. Hematology Read full story Post navigation Previous: Regulatory round-up: A month of key FDA approvals for cancer drugsNext: Regenxbio’s Duchenne gene therapy clears phase 3 hurdle Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026